Clinical trials: Biomarkers
Chronic Obstructive Pulmonary Disease
A Phase 2a Study to Assess Safety, Daily Symptoms, PK, and Biomarkers of YPL-001 in COPD Patients
This is a Phase 2a, proof-of-concept, multicenter, randomized, double-blind, double dummy, 3-treatment, parallel study, with low and high YPL 001 doses (low dose and high dose twice daily [BID]) and a placebo control in moderate…
- Trial name
- NCT02272634
- Testing
- YPL-001 80 mg, YPL-001 160 mg
- Where
- 4 sites in United States
- Volunteers
- 61 people
- Sponsor
- Yungjin Pharm. Co., Ltd.
Spinal Cord Injury, Acute Spinal Cord Injury
Prevention of Bone Loss After Acute SCI by Zoledronic Acid
The overall objective of this study is to define an effective therapeutic approach, using currently available medication, to prevent or mitigate the loss of bone mass and bone strength that occurs after acute spinal cord injury.
- Conditions
- Spinal Cord Injury, Acute Spinal Cord Injury, Bone Loss, Osteoporosis
- Trial name
- NCT02325414
- Testing
- Zoledronic acid
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- Northwestern University
Metastatic Esophageal Cancer, Gastroesophageal Cancer
Phase II Study Using CHFR Methylation Status in Patients With Metastatic Esophageal, Gastroesophageal, Gastric Cancer.
To estimate and compare the response rates in patients treated with mDCF based on methylation status of CHFR.
- Conditions
- Metastatic Esophageal Cancer, Gastroesophageal Cancer, Gastric Cancer
- Trial name
- NCT01715233
- Testing
- Docetaxel, Leucovorin, Fluorouracil
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Relapsing Multiple Sclerorsis, Multiple Sclerosis, Primary Progressive
Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS)
This is an open-label, multicenter, biomarker study designed to be hypothesis-generating in order to better understand the mechanism of action of ocrelizumab and B-cell biology in RMS or PPMS.
- Trial name
- NCT02688985
- Testing
- Ocrelizumab, Lumbar Puncture, Methyloprednisolone
- Where
- 17 sites in United States, Canada and 2 more
- Volunteers
- 131 people
- Sponsor
- Genentech, Inc.
Amyotrophic Lateral Sclerosis
A Pilot Study of Inosine in Amyotrophic Lateral Sclerosis (ALS)
This is a single center, open label, 12-week study of inosine treatment. Inosine treatment leads to an increase in the levels of urate (uric acid) in the blood.
- Trial name
- NCT02288091
- Testing
- Inosine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Biological Markers of Response to Treatment in Major Depressive Disorder
The purpose of this study is to find out if two tests are useful in predicting whether someone with depression will get better when he or she is treated with an FDA approved antidepressant medication (either citalopram or…
- Trial name
- NCT00361218
- Testing
- open-label selective serotonin reuptake inhibitor (SSRI)
- Volunteers
- 72 people
- Sponsor
- Massachusetts General Hospital
First Degree Relatives of Rheumatoid Arthritis Patients
Personalized Risk Estimator for Rheumatoid Arthritis Family Study
The purpose of this study is to understand how personalized risk factors for rheumatoid arthritis (RA) may impact willingness to change behaviors associated with RA.
- Trial name
- PRE-RA (NCT02046005)
- Testing
- PRE-RA, PRE-RA Plus, General Rheumatoid Arthritis Education
- Where
- United States
- Volunteers
- 238 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Alzheimer's Disease, Obesity
Intermittent Calorie Restriction, Insulin Resistance, and Biomarkers of Brain Function
Background: Insulin removes sugar from the blood to use for energy. Insulin resistance means that cells may not respond to insulin normally. It can lead to serious diseases.
- Conditions
- Alzheimer's Disease, Obesity, Diabetes Mellitus
- Trial name
- NCT02460783
- Testing
- Boost (R) 5-2 diet, Healthy Living Diet
- Where
- United States
- Volunteers
- 129 people, healthy volunteers welcome
- Sponsor
- National Institute on Aging (NIA)
Basal Cell Carcinoma of the Skin, Recurrent Skin Cancer
Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma
This pilot clinical trial studies arsenic trioxide in treating patients with basal cell carcinoma. Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of tumor cells, either by killing…
- Trial name
- ATO (NCT01791894)
- Testing
- arsenic trioxide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Stanford University
Liver Transplantation
Biomarkers Predicting Successful Tacrolimus Withdrawal and Everolimus (Zortress) Monotherapy Early After Liver Transplantation
Most patients who get a liver transplant must take immunosuppressants for the rest of their lives. However, this has occurred at the expense of chronic CNI toxicity, e.g.
- Trial name
- NCT02736227
- Testing
- Tacrolimus Withdrawal and Everolimus Monotherapy
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Northwestern University
Neuroendocrine Tumors
A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers
This study will investigate the safety, symptoms and biomarker response of subjects with biopsy-proven well-differentiated, low-to-intermediate-grade, unresectable, or metastatic pancreatic neuroendocrine tumors (PNETs) or or…
- Trial name
- GI-NETorPNET (NCT02132468)
- Testing
- fosbretabulin tromethamine
- Where
- 5 sites in United States
- Volunteers
- 18 people
- Sponsor
- Mateon Therapeutics
Rheumatoid Arthritis
A Biomarker Study of Secukinumab in Rheumatoid Arthritis (RA) Patients
This study aims to confirm if patients with a specific biomarker might have a better response to secukinumab treatment. To meet this purpose, exploratory biomarker studies will be done.
- Trial name
- NCT01426789
- Testing
- Secukinumab
- Where
- 36 sites in United States, Belgium and 3 more
- Volunteers
- 100 people
- Sponsor
- Novartis Pharmaceuticals
Subjective Memory Loss in Older Persons
Study of the Effects of Cerefolin NAC on Inflammation Blood Markers in Older Individuals With Memory Complaints
The purpose of this six-month research study is to determine if Cerefolin NAC reduces levels of substances in the blood that may be associated with thinking ability and the health of brain cells in subjects with memory concerns…
- Trial name
- NCT00597376
- Testing
- Cerefolin NAC (a medical food)
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Rush University Medical Center
Non-Small Cell Lung Cancer
Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy
This is an open-label, multi-centre, umbrella Phase II study in participants with metastatic NSCLC who have progressed on an anti-PD-1/PD-L1 containing therapy.
- Trial name
- HUDSON (NCT03334617)
- Testing
- Durvalumab, Danvatirsen, Ceralasertib
- Where
- 45 sites in United States, Austria and 6 more
- Volunteers
- 528 people
- Sponsor
- AstraZeneca
Idiopathic Pulmonary Fibrosis
A Study to Evaluate LTI-03 in Newly Diagnosed Idiopathic Pulmonary Fibrosis (IPF) Patients
This study will assess the safety and tolerability of inhaled LTI-03 in treatment naïve participants with newly diagnosed IPF.
- Trial name
- NCT05954988
- Testing
- LTI-03
- Where
- 7 sites in United States, Germany and 1 more
- Volunteers
- 24 people
- Sponsor
- Rein Therapeutics
Endothelial Dysfunction, Biochemical Markers
Acute Effects of E-Cigarette Aerosol Inhalation
This study comprises a portion of a larger study designed to compare results of vascular function in non-smokers to vascular function in healthy smokers chronically exposed to nicotinized electronic cigarette aerosol versus…
- Trial name
- NCT03479203
- Testing
- Electronic Cigarette Aerosol
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of Pennsylvania
Pompe Disease (Late-Onset), Glycogen Storage Disease Type II (GSD II)
Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa
This is an open-label, multicenter study of participants with late-onset Pompe disease naive to treatment with enzyme replacement therapy (ERT).
- Conditions
- Pompe Disease (Late-Onset), Glycogen Storage Disease Type II (GSD II), Glycogenesis 2 Acid Maltase Deficiency
- Trial name
- NCT01288027
- Testing
- Alglucosidase Alfa
- Where
- 15 sites in United States, Germany and 2 more
- Volunteers
- 16 people
- Sponsor
- Genzyme, a Sanofi Company
Breast Cancer
Breast Cancer Risk Biomarkers in Postmenopausal Women
This study is designed to gather information on how the prescription drug Lovaza™ which contains omega-3 fatty acids, affects blood and tissue risk biomarkers for breast cancer.
- Trial name
- NCT01252290
- Testing
- Lovaza™
- Where
- United States
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Carol Fabian, MD
Alzheimer Disease
Biomarker Predictors of Memantine Sensitivity in Patients With Alzheimer's Disease
The effects of the medication, memantine, on brain functions and the symptoms of Alzheimer's Disease will be tested
- Trial name
- NCT03703856
- Testing
- Memantine
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- University of California, San Diego
Bipolar Depression
Cyclooxygenase-2-Inhibitor Combination Treatment for Bipolar Depression
This project will attempt to enhance and augment the antidepressant efficacy of a commonly used antidepressant in poorly responding bipolar depressed patients.
- Trial name
- NCT01479829
- Testing
- Escitalopram, Celecoxib
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Loyola University